

Special Issue

Half-Life Extension of Therapeutic Antibodies

Message from the Guest Editor

The number of therapeutic antibodies in clinical development has been continuously increasing over the last several decades. Monoclonal therapeutic antibodies are established as classical immunoglobulin G (IgG)-like scaffolds such as more complex formats with novel functions and differentiated mechanisms of action. IgG1, the most abundant isotype, has the longest half-life amongst the immunoglobulins due to the pH-dependent active FcRn-mediated recycling mechanism. This Special Issue of *Antibodies* aims to collect original manuscripts and reviews covering the attempts made so far to engineer IgG-based formats for significant half-life extensions, including the research activity that was needed to understand this mechanism in more detail to repair unexpected fast clearance of complex novel IgG-based formats.

Guest Editor

Dr. Tilman Schlothauer

Roche Innovation Center, Large Molecule Research, Roche Pharma Research and Early Development (pRED), Munich, Germany

Deadline for manuscript submissions

closed (10 April 2022)



Antibodies

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 7.1
Indexed in PubMed



mdpi.com/si/95276

Antibodies
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibodies@mdpi.com

[mdpi.com/journal/
antibodies](https://mdpi.com/journal/antibodies)





Antibodies

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 7.1
Indexed in PubMed



[mdpi.com/journal/
antibodies](https://mdpi.com/journal/antibodies)



About the Journal

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Editor-in-Chief

Prof. Dr. Arne Skerra

Chair of Biological Chemistry, Technical University of Munich, Emil-Erlenmeyer-Forum 5, 85354 Freising (Weihenstephan), Germany

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

CiteScore - Q2 (Drug Discovery)